NewsroomKantesti Ltd · UK
Official news, product launches and announcements from Kantesti Ltd, the UK company behind the Kantesti AI blood test analyzer. Every release links to its source document and names the people accountable for it.
Kantesti Ltd is rolling out free Plague Check decision support in its clinic dashboard, combining exposure questions, symptoms and up to five interpreted blood reports to help doctors consider timely next steps.
Kantesti has announced Body Map and a biological blood age estimate, now live in blood test reports, with two developer APIs. The features organise flagged results by body region and explain an estimated blood…
Kantesti DNA is available to partner clinics from 28 September 2026, bringing genetic findings, interpreted blood tests and a supplement advisor into the existing clinic dashboard.
Kantesti Voice is rolling out to web reports, reading key points from written AI blood test interpretations aloud in about two minutes. Free demos include a short results summary; premium reports include both parts.
Author & spokesperson
Founder & CEO, Kantesti Ltd
Julian Emirhan Bulut is the founder and Chief Executive Officer of Kantesti Ltd. A medical AI specialist educated at the University of Milan, he leads the design of the Kantesti AI blood test analyzer, its neural-network interpretation engine and its multilingual reporting, and is accountable for every product announcement the company makes.
Clinical oversight
Chief Medical Officer (CMO), Kantesti Ltd
Dr. Thomas Klein is a board-certified clinical hematologist and internist with over 15 years of experience in laboratory medicine and AI-assisted clinical analysis. As Chief Medical Officer at Kantesti, he provides clinical oversight of the medical accuracy of the platform and reviews clinical statements in Kantesti publications.
